Reata Pharmaceuticals Other Current Liabilities

Reata Pharmaceuticals (RETA) currently reports a other current liabilities of $18M as of June 2023. That compares with $39M in the prior-year period — down 52.7% year over year. Use the charts on this page to explore Reata Pharmaceuticals's other current liabilities history and peer comparisons.

Reata Pharmaceuticals's other current liabilities decreased from $39M to $18M — a 52.7% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals reported $18M in other current liabilities as of June 2023. That compares with $39M in the prior-year period — down 52.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.